ArticleJournal of neuro-oncology2013
Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.Journal of neuro-oncology · 2023Pooled it
- Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.Acta neurochirurgica · 2021Pooled it
- Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.Radiation oncology (London, England) · 2014Trial
- Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Point/Counterpoint: The role of reirradiation in recurrent glioblastoma.Neuro-oncology · 2025Article
- High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy.Scientific reports · 2020Article
- The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.Clinical and translational radiation oncology · 2020Article
- Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.Journal of cancer research and clinical oncology · 2020Article
- Long-term outcome data from 121 patients treated with Gamma Knife stereotactic radiosurgery as salvage therapy for focally recurrent high-grade gliomas.Journal of radiosurgery and SBRT · 2019Article
- Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study.Neurologia medico-chirurgica · 2018Article
- From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Modern reirradiation for recurrent gliomas can safely delay tumor progression.Neuro-oncology practice · 2018Article
- Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.Journal of neuro-oncology · 2018Article
- The radiosurgery fractionation quandary: single fraction or hypofractionation?Neuro-oncology · 2017Article
- Article
- Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.Journal of neuro-oncology · 2016Article
- Re-irradiation alternatives for recurrent high-grade glioma.Oncology letters · 2016Article
- Efficacy and safety of bevacizumab for the treatment of glioblastoma.Experimental and therapeutic medicine · 2016Article
- Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Oncotarget · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal treatment for recurrent high-grade gliomas is unknown and a standard of care does not exist. Re-irradiation with concomitant bevacizumab represents an option. Retrospectively, we analyzed a cohort of heavily pretreated patients (n = 14) with relapsing HGGs who underwent re-irradiation with conventional 3D-conformal or intensified modulated radiotherapy (IMRT). Ten of them received re-irradiation in combination with bevacizumab. The study population consisted of eight GBMs and six anaplastic gliomas. All patients had previously undergone irradiation for first-line therapy, including seven patients with radiochemotherapy with temozolomide. Patients without contraindications started with two infusions of bevacizumab (10 mg/kg of body weight every other week) prior to re-irradiation and continued through re-irradiation until progression. The median patient age was 45 years with a median Karnofsky performance scale of 70. The median dose of re-irradiation was 41.6 Gy [39-55 Gy]. The median physical cumulative radiation dose was 101.6 Gy [65-110.4 Gy]. The median PFS from re-irradiation was 5.1 months [1.6-17.4] based on clinical and RANO criteria. Median OS from re-irradiation was 9.0 months [6.4-17.8]. We detected radionecrosis due to advanced imaging in one patient. Other toxicities were expected and attributable well known side effects of bevacizumab. This retrospective study provides additional feasibility and safety data of conventional 3D-conformal re-irradiation and IMRT in combination with bevacizumab in relapsing high-grade gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.